You finance buying a pharmacy business with a blend of a term acquisition loan (most commonly an SBA 7(a) loan for retail and independent pharmacies) plus buyer equity of roughly 10-20% and, frequently, a seller note that covers part of the price. That structure handles the purchase itself. What it rarely covers well is the working capital gap after closing — the inventory rebuild, the 15-45 day lag on pharmacy benefit manager (PBM) and insurance reimbursements, and payroll for the technicians and pharmacist who keep the doors open. That gap is where revenue-based financing, approved on the pharmacy's bank deposits and revenue rather than your personal credit, tends to do the real work for buyers.
Below is how an underwriter looks at a pharmacy acquisition: which financing tools fit which situation, what the deal has to prove, realistic example terms, and a decision framework for when each option works and when to walk away from it.
Key takeaways
- Pharmacy acquisitions are usually financed as a blend: an SBA 7(a) or conventional acquisition loan, buyer equity of roughly 10-20%, and often a seller note covering part of the price.
- Prescription files are the single most valuable asset in an independent pharmacy purchase; a declining script count is a red flag no valuation multiple hides.
- The 15-45 day lag on PBM and insurance reimbursements is the top reason well-bought pharmacies miss payroll shortly after closing.
- Revenue-based financing approves on the pharmacy's bank deposits and revenue rather than credit, considers FICO 500+, starts around a $10,000 minimum, and funds in about 24-48 hours.
- SBA 7(a) acquisition loans commonly take 60-90 days to close, so timing-sensitive deals often need a bridge.
- DEA registration, state board licensure, and a Medicare/Medicaid change-of-ownership (CHOW) filing must be sequenced so you can dispense and bill without a revenue gap.
- No legitimate funder guarantees approval or terms before underwriting the business and the buyer.
What buying a pharmacy actually costs to finance
A pharmacy acquisition is not one number. Underwriters break the financing need into distinct buckets, because each is funded by a different instrument:
- The purchase price — usually valued as a multiple of adjusted EBITDA (seller's discretionary earnings), often in the 2x-4x range for an independent, plus the value of prescription files, which are the single most valuable intangible asset in the deal.
- Inventory — pharmacy inventory (especially brand and specialty drugs) is expensive and moves fast. It is sometimes bundled into the price, sometimes bought separately at cost on the day of closing.
- Working capital after close — the quiet deal-killer. Third-party reimbursements from PBMs and insurers land on a delay, but your suppliers, wholesaler (McKesson, Cardinal, AmerisourceBergen/Cencora), rent, and payroll do not wait.
- Transition costs — DEA and state board of pharmacy license transfers, change-of-ownership (CHOW) filings with Medicare/Medicaid, PBM re-credentialing, and legal/escrow fees.
A buyer who finances only the purchase price and forgets the reimbursement lag can be technically solvent and still miss payroll in month two. Model all four buckets before you sign.
The main ways to finance a pharmacy purchase
These are the tools that fund pharmacy acquisitions, in rough order of how often they carry the deal:
- SBA 7(a) loan. The workhorse for independent and retail pharmacy buyouts. Up to $5 million, long amortization (often 10 years for a business-only purchase, up to 25 if real estate is included), and lower down payment than conventional. Trade-off: heavy documentation, personal guarantee, collateral and often a lien on your home, and a timeline that commonly runs 60-90 days.
- Conventional bank acquisition loan. Faster than SBA for a strong borrower with a clean, profitable target, but usually wants more equity down and stronger personal financials.
- Seller financing (seller note). Extremely common and underrated. The seller carries 10-30% of the price as a note, which lowers your cash-in, signals the seller believes in the business, and is viewed favorably by SBA lenders (a standby seller note can even count toward equity).
- Revenue-based financing / MCA marketplace. Approval driven by the pharmacy's bank deposits and revenue, not your credit score. Minimum funding around $10,000, FICO 500+ considered, and funds in roughly 24-48 hours. It doesn't replace the acquisition loan — it fills the working-capital and reimbursement-lag gap the term loan leaves open, or bridges you while an SBA file is still in underwriting. See our working capital financing guide for how this sits next to a term loan.
- Rollover for business startups (ROBS) / retirement funds. Some buyers fund equity from a 401(k) rollover. Powerful but structurally complex — get a specialist and a CPA before going near it.
How an underwriter reviews a pharmacy acquisition
Whether the money comes from an SBA lender or a revenue-based funder, the same questions decide the deal. Know them before you apply:
- Revenue quality and reimbursement mix. How much of the top line is cash pay vs. third-party (PBM/insurance/Medicare/Medicaid)? A heavy reliance on a single PBM contract or one large 340B relationship is a concentration risk. Reimbursement pressure and DIR fees are the structural headwind in this industry — lenders know it.
- Prescription volume and file value. Scripts filled per day and the size/stickiness of the patient base. Prescription files are the core asset; a declining script count is a red flag no multiple can hide.
- Bank deposits and cash flow. For revenue-based approval this is the whole game — 3-6 months of business bank statements showing consistent deposits. Underwriters read deposit regularity, not just totals.
- Licensing and clean transfer. DEA registration, state board licensure, and a workable CHOW plan. A gap where you can't dispense or can't bill Medicare is a revenue hole, and lenders price it in.
- The pharmacist question. Are you a pharmacist, or are you retaining one? A non-pharmacist buyer without a committed pharmacist-in-charge is a materially riskier file.
Realistic example financing structures
The figures below are illustrative structures for a hypothetical independent pharmacy purchase, shown to demonstrate how the pieces fit — not quotes, offers, or predictions. Your terms depend on the target's financials and your profile.
| Deal component | Example A: SBA-led buyout | Example B: Revenue-based bridge |
|---|---|---|
| Scenario | Profitable independent, buyer has 15% down | Buyer closing soon, needs post-close working capital |
| Primary instrument | SBA 7(a) acquisition loan | Revenue-based financing on pharmacy deposits |
| Buyer equity (for example) | ~10-20% of price | Not required — approval on revenue |
| Seller note (for example) | ~10-20% on standby | N/A |
| Approval basis | Credit, collateral, cash flow, personal guarantee | Bank deposits + revenue; FICO 500+ considered |
| Typical funding speed | ~60-90 days | ~24-48 hours |
| Minimum size | Larger; suited to the full purchase | From ~$10,000 |
| Best role in the deal | Funds the purchase itself | Covers reimbursement lag, inventory, payroll gap |
The most common real-world outcome is a combination: SBA or conventional loan plus a seller note to buy the pharmacy, and revenue-based financing standing by to smooth the first few months of PBM reimbursement lag. Repayment on the revenue-based side flexes with your daily or weekly deposits rather than a fixed bank amortization, which is the point of using it for a cash-flow gap.
Decision framework: when each option works, and when to avoid it
Use an SBA 7(a) loan when the target is genuinely profitable, you can document it, you have 10-20% to put down (or a seller willing to carry a standby note), and you can wait 60-90 days to close. It is the cheapest capital per dollar for most pharmacy buyers.
Avoid leaning on SBA when the seller needs to close fast, the financials are messy or trending down, or the timeline can't absorb a multi-month underwriting process — the deal may die on the calendar.
Use seller financing when you want to lower cash-in, align the seller's incentives with a smooth transition, and strengthen an SBA application. Push for it in almost every deal.
Use revenue-based financing when the acquisition loan is in place or nearly so, and the real problem is the gap after close: rebuilding inventory, covering payroll while PBM reimbursements catch up, or bridging weeks between closing and your first clean billing cycle. It approves on the business's deposits and revenue, considers FICO 500+, funds in about 24-48 hours, and starts around a $10,000 minimum.
Avoid revenue-based financing when you are trying to fund the entire purchase price with it, or when the pharmacy's margins are already thin and volatile — matching a revenue-linked repayment against unstable cash flow compounds the problem instead of solving it. It is a bridge and a working-capital tool, not a substitute for an acquisition loan. And no legitimate funder should ever call approval or terms "guaranteed" — treat that word as a warning sign.
Pharmacy-specific risks that change your financing plan
Pharmacies are not generic retail, and these industry realities should shape how much you borrow and how you structure it:
- Reimbursement lag is structural, not occasional. Build a working-capital cushion for the 15-45 day gap on third-party pay. This is the number one reason well-bought pharmacies stumble after close.
- DIR fees and PBM pressure compress margins. Underwrite the business on realistic net reimbursement, not gross script revenue.
- Inventory is capital-intensive and dated. Verify inventory value at close and watch for slow-moving or short-dated stock that inflates the price.
- License and CHOW timing can create a revenue gap. If your DEA transfer, state licensure, or Medicare/Medicaid CHOW isn't sequenced correctly, you may operate weeks before you can bill. Plan financing to survive that window.
- Owner and prescriber relationships walk. In independents, a lot of loyalty attaches to the departing pharmacist. A transition/retention plan protects the revenue your loan is underwritten on.
For how to size and structure the cash-flow buffer specifically, our working capital financing guide walks through the math without touching your acquisition loan.
How to prepare a fundable pharmacy acquisition file
Move faster and get better terms by having this ready before you approach any funder:
- Three years of the target's financials — tax returns, P&Ls, and balance sheets, plus a seller's discretionary earnings (SDE) adjustment schedule.
- Script data — daily prescription volume, payer mix, and any PBM/340B contract details.
- 3-6 months of the pharmacy's business bank statements — the core of a revenue-based approval and useful for every lender.
- Your personal financial statement and resume — especially anything showing pharmacy or retail-management experience.
- Letter of intent and draft purchase agreement — including how inventory and prescription files are treated.
- A transition plan — pharmacist-in-charge, staff retention, and license/CHOW timeline.
A buyer who walks in with the bank statements, the script data, and a credible transition plan gets underwritten as a serious operator — which is exactly what separates a funded deal from a stalled one.
Frequently asked questions
Can I buy a pharmacy with no money down?
Rarely with a single loan. Most acquisition financing expects buyer equity of roughly 10-20%, though a standby seller note can reduce or, in some SBA structures, partly stand in for your cash. Revenue-based financing doesn't require a down payment because it approves on the pharmacy's revenue, but it's a working-capital and bridge tool, not a way to fund the entire purchase price.
What credit score do I need to finance a pharmacy purchase?
For an SBA or conventional acquisition loan, lenders generally look for solid personal credit, usually 650+, along with cash flow and collateral. Revenue-based financing is far more flexible: it weighs the business's bank deposits and revenue over your credit and will consider FICO 500+. That's why buyers with thinner credit often use revenue-based funding for the post-close gap.
How long does pharmacy acquisition financing take?
An SBA 7(a) loan commonly takes 60-90 days from application to closing because of documentation, appraisal, and license considerations. A conventional loan can be faster for a strong borrower. Revenue-based financing typically funds in about 24-48 hours, which is why it's often used to bridge timing or cover working capital while a term loan is still in underwriting.
Should I use an SBA loan or revenue-based financing?
They solve different problems. An SBA 7(a) loan is the cheapest capital to buy the pharmacy itself and should anchor most deals. Revenue-based financing fills the gap the term loan leaves — inventory rebuild, payroll, and the 15-45 day PBM reimbursement lag after close. Many buyers use both: SBA plus a seller note to purchase, revenue-based funding to smooth the first months.
How much working capital do I need after buying a pharmacy?
Enough to cover the reimbursement lag on third-party pay plus normal operating costs for at least the first one to two months. Because PBM and insurance payments land on a delay while wholesaler, rent, and payroll do not, this cushion is what keeps a well-bought pharmacy from missing payroll early. Size it against your payer mix before closing, not after.
Does seller financing help me get approved?
Yes. A seller note lowers your cash-in and signals that the seller believes the business will keep performing. SBA lenders view a standby seller note favorably, and in some structures it can count toward your required equity. Push for seller financing in nearly every pharmacy deal — it strengthens both your cash position and your loan application.
What's the biggest financing mistake pharmacy buyers make?
Financing only the purchase price and forgetting the reimbursement lag. A buyer can close a profitable pharmacy and still miss payroll in month two because PBM and insurance reimbursements arrive weeks after the bills do. Model the working-capital gap as its own line item and have a bridge, such as revenue-based financing, arranged before closing.
Is financing ever guaranteed for a pharmacy purchase?
No. Any funder or broker that promises guaranteed approval or guaranteed terms before reviewing the target's financials and your profile should be treated as a warning sign. Legitimate acquisition and revenue-based funding both depend on real underwriting — the pharmacy's revenue and cash flow, your file, and the structure of the deal.
